Keywords: FDA, Transparency Task Force, Biosimilars, Complete response letters

FDA Transparency Task Force unveils draft proposals for more public disclosure relating to pharma; agency to appoint biosimilars director

Article | 20 May 2010

The US Food and Drug Administration’s Transparency Task Force yesterday released 21 draft proposals for public comment on public disclosure ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in